Mechanisms of cytotoxic lymphocyte-mediated apoptosis and relationship with the tumor suppressor p53

Critical Reviews in Immunology

Volumn 35, Issue 6, 2015, Pages 433-449

  Thiery, Jerome ^a,b,c   Safta, Thouraya Ben ^a,b,c   Ziani, Linda ^a,b,c   Chouaib, Salem ^a,b,c  

^a Faculty of Medicine University of Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Apoptosis; Cytotoxic lymphocytes; Death domain receptors; Granzymes; P53

Indexed keywords

CASPASE 8; DEATH RECEPTOR; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEATH RECEPTOR 6; FAS ANTIGEN; GRANZYME A; GRANZYME B; PERFORIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL STRESS; CYTOTOXIC T LYMPHOCYTE; DNA FRAGMENTATION; EFFECTOR CELL; ENDOPLASMIC RETICULUM; EXCISION REPAIR; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84964076453     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2016015691     Document Type: Review

References (128)

1. Lieberman J. Anatomy of a murder: how cytotoxic T cells and NK cells are activated, develop, and eliminate their targets. Immunol Revs. 2010;235(1):5-9. Epub 2010/06/12.
2. Ashkenazi A, Salvesen G. Regulated Cell Death: Signaling and mechanisms. Annual Rev Cell Dev Biology. 2014;30:337-56. Epub 2014/08/26.
3. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184(5):1781-90. Epub 1996/11/01.
4. Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nature Rev. 2015;15(6):388-400. Epub 2015/05/23.
5. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 2001;167(4):2068-73. Epub 2001/08/08.
6. Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ. 2012;19(1):28-35. Epub 2011/11/05.
7. Susanto O, Trapani JA, Brasacchio D. Controversies in granzyme biology. Tissue Antigens. 2012;80(6):477-87. Epub 2012/11/10.
8. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nature Rev. 2003;3(5):361-70.
9. Krzewski K, Coligan JE. Human NK cell lytic granules and regulation of their exocytosis. Front Immunol. 2012;3:335. Epub 2012/11/20.
10. Thiery J, Lieberman J. Perforin: A key pore-forming protein for immune control of viruses and cancer. Subcell Biochem. 2014;80:197-220. Epub 2014/05/07.
11. Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol. 2010;37(6):1361-78.
12. Raja SM, Metkar SS, Honing S, Wang B, Russin WA, Pipalia NH, Menaa C, Belting M, Cao X, Dressel R, Froelich CJ. A novel mechanism for protein delivery: granzyme B undergoes electrostatic exchange from serglycin to target cells. J Biol Chem. 2005;280(21):20752-61. Epub 2005/03/25.
13. Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, Martinvalet D, Goping IS, Bleackley RC, Kirchhausen T, Lieberman J. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nature Immun. 2011;12(8):770-7. Epub 2011/06/21.
14. Thiery J, Keefe D, Saffarian S, Martinvalet D, Walch M, Boucrot E, Kirchhausen T, Lieberman J. Perforin activates clathrin-and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood. 2010;115(8):1582-93.
15. Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, D'Angelo ME, Orlova EV, Coulibaly F, Verschoor S, Browne KA, Ciccone A, Kuiper MJ, Bird PI, Trapani JA, Saibil HR, Whisstock JC. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468(7322):447-51. Epub 2010/11/03.
16. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annual Rev Immuny. 2008;26:389-420. Epub 2008/02/29.
17. Anthony DA, Andrews DM, Watt SV, Trapani JA, Smyth MJ. Functional dissection of the granzyme family: cell death and inflammation. Immunol Rev. 2010;235(1):73-92. Epub 2010/06/12.
18. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC. Granzyme B-mediated cytochrome C release is regulated by the Bcl-2 family members Bid and Bax. J Exp Med. 2000;192(10):1391-402.
19. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, Trapani JA. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med. 2000;192(10):1403-14. Epub 2000/11/21.
20. Wang GQ, Wieckowski E, Goldstein LA, Gastman BR, Rabinovitz A, Gambotto A, Li S, Fang B, Yin XM, Rabinowich H. Resistance to granzyme B-mediated cytochrome C release in Bak-deficient cells. J Exp Med. 2001;194(9):1325-37. Epub 2001/11/07.
21. Jacquemin G, Margiotta D, Kasahara A, Bassoy EY, Walch M, Thiery J, Lieberman J, Martinvalet D. Granzyme B-induced mitochondrial ROS are required for apoptosis. Cell Death and Differentiation. 2014. Epub 2014/11/02.
22. Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC, Green DR. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem. 2001;276(15):12060-7. Epub 2001/03/30.
23. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity. 2003;18(3):319-29.
24. Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ. Granzyme B can cause mitochondrial depolarization and cell death in the absence of Bid, Bax, and Bak. Proc Nat Acad Sci U S A. 2001;98(26):14985-90.
25. Thomas DA, Du C, Xu M, Wang X, Ley TJ. Dff45/Icad can be directly processed by granzyme B during the induction of apoptosis. Immunity. 2000;12(6):621-32. Epub 2000/07/14.
26. Sharif-Askari E, Alam A, Rheaume E, Beresford PJ, Scotto C, Sharma K, Lee D, DeWolf WE, Nuttall ME, Lieberman J, Sekaly RP. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated dnase release and DNA fragmentation. EMBO J. 2001;20(12):3101-13. Epub 2001/06/19.
27. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for Ctl-induced apoptosis. Immunity. 1998;8(4):451-60. Epub 1998/05/20.
28. Zhang D, Beresford PJ, Greenberg AH, Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc of National Academy of Sciences of the United States of America. 2001;98(10):5746-51. Epub 2001/05/02.
29. Lieberman J. Granzyme a activates another way to die. Immunol Rev. 2010;235(1):93-104. Epub 2010/06/12.
30. Martinvalet D, Zhu P, Lieberman J. Granzyme a induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005;22(3):355-70. Epub 2005/03/23.
31. Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J. Granzyme a cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell. 2008;133(4):681-92. Epub 2008/05/20.
32. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001;276(46):43285-93. Epub 2001/09/14.
33. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW, Lieberman J. The Exonuclease Trex1 is in the set complex and acts in concert with Nm23-H1 to degrade DNA during granzyme A-mediated cell death. Molec Cell. 2006;23(1):133-42. Epub 2006/07/05.
34. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor Nm23-H1 is a granzyme A-activated dnase during Ctl-mediated apoptosis, and the nucleosome assembly protein set is its inhibitor. Cell. 2003;112(5):659-72. Epub 2003/03/12.
35. Fan Z, Beresford PJ, Zhang D, Lieberman J. Hmg2 interacts with the nucleosome assembly protein set and is a target of the cytotoxic T-lymphocyte protease granzyme A. Molec Cell Biol. 2002;22(8):2810-20. Epub 2002/03/23.
36. Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, Lieberman J. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nature Immunol. 2003;4(2):145-53. Epub 2003/01/14.
37. Zhu P, Martinvalet D, Chowdhury D, Zhang D, Schlesinger A, Lieberman J. The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1. Blood. 2009;114(6):1205-16. Epub 2009/06/10.
38. Zhu P, Zhang D, Chowdhury D, Martinvalet D, Keefe D, Shi L, Lieberman J. Granzyme A, which causes single-stranded DNA Damage, targets the double-strand break repair protein KU70. EMBO reports. 2006;7(4):431-7. Epub 2006/01/28.
39. Bovenschen N, Kummer JA. Orphan granzymes find a home. Immunolog Rev. 2010;235(1):117-27. Epub 2010/06/12.
40. Andrade F, Fellows E, Jenne DE, Rosen A, Young CS. Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. EMBO J. 2007;26(8):2148-57. Epub 2007/03/17.
41. Andrade F. Non-cytotoxic antiviral activities of granzymes in the context of the immune antiviral state. Immunolog Rev. 2010;235(1):128-46. Epub 2010/06/12.
42. Fellows E, Gil-Parrado S, Jenne DE, Kurschus FC. Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood. 2007;110(2):544-52. Epub 2007/04/06.
43. Zhao T, Zhang H, Guo Y, Fan Z. Granzyme K directly processes bid to release cytochrome C and endonuclease G leading to mitochondria-dependent cell death. J Biol Chem. 2007;282(16):12104-11. Epub 2007/02/20.
44. Zhao T, Zhang H, Guo Y, Zhang Q, Hua G, Lu H, Hou Q, Liu H, Fan Z. Granzyme K cleaves the nucleosome assembly protein set to induce single-stranded DNA nicks of target cells. Cell Death Differ. 2007;14(3):489-99. Epub 2006/09/30.
45. Guo Y, Chen J, Zhao T, Fan Z. Granzyme K degrades the redox/DNA repair enzyme ape1 to trigger oxidative stress of target cells leading to cytotoxicity. Molecular Immunology. 2008;45(8):2225-35. Epub 2008/01/09.
46. Guo Y, Chen J, Shi L, Fan Z. Valosin-containing protein cleavage by granzyme K accelerates an endoplasmic reticulum stress leading to caspase-independent cytotoxicity of target tumor cells. J Immunol. 2010;185(9):5348-59. Epub 2010/09/30.
47. Kelly JM, Waterhouse NJ, Cretney E, Browne KA, Ellis S, Trapani JA, Smyth MJ. Granzyme M mediates a novel form of perforin-dependent cell death. J Biol Chem. 2004;279(21):22236-42. Epub 2004/03/19.
48. Bovenschen N, de Koning PJ, Quadir R, Broekhuizen R, Damen JM, Froelich CJ, Slijper M, Kummer JA. NK cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J Immunol. 2008;180(12):8184-91. Epub 2008/06/05.
49. Lu H, Hou Q, Zhao T, Zhang H, Zhang Q, Wu L, Fan Z. Granzyme M directly cleaves inhibitor of caspase-activated Dnase (Cad) to unleash cad leading to DNA fragmentation. J Immunol. 2006;177(2):1171-8. Epub 2006/07/05.
50. Hu D, Liu S, Shi L, Li C, Wu L, Fan Z. Cleavage of survivin by granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (Xiap) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem. 2010;285(24):18326-35. Epub 2010/04/22.
51. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunol. 2009;10(4):348-55. Epub 2009/03/20.
52. Lavrik IN. Systems biology of death receptor networks: live and let die. Cell Death Dis. 2014;5:e1259. Epub 2014/05/31.
53. Falschlehner C, Schaefer U, Walczak H. Following Trail's path in the immune system. Immunology. 2009;127(2):145-54. Epub 2009/05/30.
54. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F. Regulation of soluble and surface-bound Trail in human T cells, B cells, and monocytes. Cytokine. 2003;24(6):244-53. Epub 2003/11/12.
55. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry. 2002;41(30):9462-9. Epub 2002/07/24.
56. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280(49):40599-608. Epub 2005/10/18.
57. Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, Krammer PH, Lavrik IN, Eils R. Dynamics within the Cd95 death-inducing signaling complex decide life and death of cells. Molec Sys Biol. 2010;6:352. Epub 2010/03/10.
58. Micheau O, Tschopp J. Induction of Tnf receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181-90. Epub 2003/07/31.
59. Walczak H. Tnf and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Revs. 2011;244(1):9-28. Epub 2011/10/25.
60. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288(5475):2354-7. Epub 2000/07/06.
61. Feig C, Tchikov V, Schutze S, Peter ME. Palmitoylation of Cd95 facilitates formation of sds-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007;26(1):221-31. Epub 2006/12/13.
62. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, Robinson H, Salvesen GS, Schwarzenbacher R, Riedl SJ. The Fas-Fadd death domain complex structure unravels signalling by receptor clustering. Nature. 2009;457(7232):1019-22. Epub 2009/01/02.
63. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. Fadd/Mort1 and caspase-8 are recruited to Trail receptors 1 and 2 and are essential for apoptosis mediated by Trail receptor 2. Immunity. 2000;12(6):599-609. Epub 2000/07/14.
64. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent Apo-1 (Fas/Cd95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579-88. Epub 1995/11/15.
65. Mace PD, Riedl SJ. Molecular cell death platforms and assemblies. Curr Opin Cell Biol. 2010;22(6):828-36. Epub 2010/09/08.
66. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two Cd95 (Apo-1/Fas) signaling pathways. EMBO J. 1998;17(6):1675-87. Epub 1998/05/02.
67. Schleich K, Warnken U, Fricker N, Ozturk S, Richter P, Kammerer K, Schnolzer M, Krammer PH, Lavrik IN. Stoichiometry of the cd95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Molec Cell. 2012;47(2):306-19. Epub 2012/06/12.
68. Lavrik IN, Krammer PH. Regulation of Cd95/Fas signaling at the DISC. Cell Death Differ. 2012;19(1):36-41. Epub 2011/11/15.
69. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in Cd95 type I and type II cells. J Biol Chem. 1999;274(32):22532-8. Epub 1999/07/31.
70. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-Flice, a novel inhibitor of tumor necrosis factor receptor-1-and Cd-95-induced apoptosis. J Biol Chem. 1997;272(28):17255-7. Epub 1997/07/11.
71. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular flip. Nature. 1997;388(6638):190-5. Epub 1997/07/10.
72. Ozturk S, Schleich K, Lavrik IN. Cellular flice-like inhibitory proteins (C-flips): fine-tuners of life and death decisions. Exp Cell Res. 2012;318(11):1324-31. Epub 2012/02/09.
73. Kruse JP, Gu W. Modes of P53 Regulation. Cell. 2009;137(4):609-22. Epub 2009/05/20.
74. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1992;1(1):45-9.
75. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413-31. Epub 2009/05/05.
76. Nakano K, Vousden KH. Puma, a novel proapoptotic gene, is induced by P53. Molec Cell. 2001;7(3):683-94. Epub 2001/07/21.
77. Miyashita T, Reed JC. Tumor suppressor P53 is a direct transcriptional activator of the human Bax gene. Cell. 1995;80(2):293-9. Epub 1995/01/27.
78. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a Bh3-only member of the Bcl-2 family and candidate mediator of P53-induced apoptosis. Science New York, NY. 2000;288(5468):1053-8. Epub 2000/05/12.
79. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The Bcl-2 family reunion. Molecular Cell. 2010;37(3):299-310. Epub 2010/02/18.
80. Hermeking H. Micrornas in the P53 Network: micromanagement of tumour suppression. Nature Rev Cancer. 2012;12(9):613-26. Epub 2012/08/18.
81. Speidel D. Transcription-Independent P53 Apoptosis: an alternative route to death. Trends Cell Biol. 2010;20(1):14-24. Epub 2009/11/03.
82. Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: Bcl-2 family proteins and apoptosis. Cell Death Differ. 2014;21(2):206-15. Epub 2013/10/29.
83. Galluzzi L, Morselli E, Kepp O, Vitale I, Pinti M, Kroemer G. Mitochondrial liaisons of p53. Antiox Redox Signal. 2011;15(6):1691-714. Epub 2010/08/18.
84. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. Bcl-2, Bcl-X(L) sequester Bh3 domain-only molecules preventing Bax-and Bak-mediated mitochondrial apoptosis. Molec Cell. 2001;8(3):705-11. Epub 2001/10/05.
85. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. A unified model of mammalian Bcl-2 protein family interactions at the mitochondria. Molec Cell. 2011;44(4):517-31. Epub 2011/11/01.
86. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007;26(4):923-34. Epub 2007/02/03.
87. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. P53 has a direct apoptogenic role at the mitochondria. Molec Cell. 2003;11(3):577-90.
88. Petros AM, Gunasekera A, Xu N, Olejniczak ET, Fesik SW. Defining the p53 DNA-binding domain/Bcl-X(L)-binding interface using nmr. FEBS Letts. 2004;559(1-3):171-4. Epub 2004/02/13.
89. Hagn F, Klein C, Demmer O, Marchenko N, Vaseva A, Moll UM, Kessler H. Bclxl changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem. 2010;285(5):3439-50. Epub 2009/12/04.
90. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, Pan H, Kessler H, Pancoska P, Moll UM. Wt p53, but not tumor-derived mutants, bind to bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006;281(13):8600-6. Epub 2006/01/31.
91. Follis AV, Llambi F, Ou L, Baran K, Green DR, Kriwacki RW. The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nature Struct Molec Biol. 2014;21(6):535-43. Epub 2014/05/13.
92. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010-4.
93. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. Puma couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005;309(5741):1732-5.
94. Vousden KH. Apoptosis. P53 and Puma: a deadly duo. Science. 2005;309(5741):1685-6. Epub 2005/09/10.
95. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nature Cell Biol. 2004;6(5):443-50. Epub 2004/04/13.
96. Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem. 2010;285(29):22473-83. Epub 2010/04/21.
97. Hua G, Wang S, Zhong C, Xue P, Fan Z. Ignition of P53 bomb sensitizes tumor cells to granzyme K-mediated cytolysis. J Immunol. 2009;182(4):2152-9. Epub 2009/02/10.
98. Meslin F, Thiery J, Richon C, Jalil A, Chouaib S. Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells. J Biol Chem. 2007;282(45):32991-9.
99. Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, Lejeune F, Tibbetts RS, Maquat LE, Abraham RT. The Mrna surveillance protein hsmg-1 functions in genotoxic stress response pathways in mammalian cells. Molec Cell. 2004;14(5):585-98. Epub 2004/06/04.
100. Meslin F, Hamai A, Mlecnik B, Rosselli F, Richon C, Jalil A, Wemhoff G, Thiery J, Galon J, Chouaib S. Hsmg-1 is a granzyme B-associated stress-responsive protein kinase. J Molecular Med (Berlin, Germany). 2011;89(4):411-21.
101. Ben Safta T, Ziani L, Favre L, Lamendour L, Gros G, Mami-Chouaib F, Martinvalet D, Chouaib S, Thiery J. Granzyme B-activated p53 interacts with bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol. 2014. Epub 2014/11/19.
102. Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Brit J Pharmacol. 2013;169(8):1723-44. Epub 2013/05/04.
103. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19(3-4):325-31. Epub 2008/05/23.
104. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and trail receptor pathway. Oncogene. 2008;27(48):6207-15. Epub 2008/10/22.
105. Liu X, Yue P, Khuri FR, Sun SY. P53 Upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004;64(15):5078-83. Epub 2004/08/04.
106. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the killer/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 2000;19(14):1735-43. Epub 2000/04/25.
107. Henry RE, Andrysik Z, Paris R, Galbraith MD, Espinosa JM. A Dr4:Tbid axis drives the p53 apoptotic response by promoting oligomerization of poised bax. EMBO J. 2012;31(5):1266-78. Epub 2012/01/17.
108. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/Apo-1 expression. Molec Cell Biol. 1995;15(6):3032-40. Epub 1995/06/01.
109. Zhao J, Lu Y, Shen HM. Targeting p53 as a therapeutic strategy in sensitizing trail-induced apoptosis in cancer cells. Cancer Letts. 2012;314(1):8-23. Epub 2011/10/28.
110. Taketani K, Kawauchi J, Tanaka-Okamoto M, Ishizaki H, Tanaka Y, Sakai T, Miyoshi J, Maehara Y, Kitajima S. Key role of Atf3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells. Oncogene. 2012;31(17):2210-21. Epub 2011/09/20.
111. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Tnfsf10 (Trail), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008;7(12):2034-8. Epub 2008/12/25.
112. Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2l/trail-induced apoptosis. Cell Death Differ. 2008;15(4):718-29. Epub 2008/01/19.
113. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. triptolide sensitizes aml cells to trail-induced apoptosis via decrease of Xiap and p53-mediated increase of DR5. Blood. 2008;111(7):3742-50. Epub 2008/01/12.
114. Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG, de Jong S. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective trail over RHTrail. British J Cancer. 2013;109(10):2685-95. Epub 2013/10/19.
115. Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene. 1997;15(23):2817-26. Epub 1998/01/07.
116. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, Stancou R, Badie C, Haddada H, Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF-resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and rb. Oncogene. 1999;18(39):5464-72. Epub 1999/09/28.
117. Ameyar-Zazoua M, Larochette N, Dorothee G, Daugas E, Haddada H, Gouloumet V, Metivier D, Stancou R, Mami-Chouaib F, Kroemer G, Chouaib S. Wild-type p53 induced sensitization of mutant p53 TNF-resistant cells: role of caspase-8 and mitochondria. Cancer Gene Therapy. 2002;9(3):219-27. Epub 2002/03/16.
118. Muret J, Hasmim M, Stasik I, Jalil A, Mallavialle A, Nanbakhsh A, Lacroix L, Billot K, Baud V, Thiery J, Vielh P, Terrier P, Wiels J, Vassilev L, Lecesne A, Bonvalot S, Chouaib S. Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-Alpha by restoring p53 function. PloS One. 2012;7(6):e38808. Epub 2012/06/22.
119. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, Krammer PH, Rosl F. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene. 2002;21(2):165-75. Epub 2002/01/23.
120. Senatus PB, Li Y, Mandigo C, Nichols G, Moise G, Mao Y, Brown MD, Anderson RC, Parsa AT, Brandt-Rauf PW, Bruce JN, Fine RL. Restoration of p53 function for selective fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 cooh-terminal peptide. Molecular Cancer Therapeutics. 2006;5(1):20-8. Epub 2006/01/25.
121. Thiery J, Dorothee G, Haddada H, Echchakir H, Richon C, Stancou R, Vergnon I, Benard J, Mami-Chouaib F, Chouaib S. Potentiation of a tumor cell susceptibility to autologous ctl killing by restoration of wild-type p53 function. J Immunol. 2003;170(12):5919-26.
122. Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, Mami-Chouaib F, Chouaib S. P53 potentiation of tumor cell susceptibility to cytotoxic T lymphocyte involves fas and mitochondrial pathways. J Immunol. 2005;174(2):871-8.
123. Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschopp J, Tanaka N. Accelerated degradation of cellular flip protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene. 2001;20(37):5225-31. Epub 2001/08/30.
124. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the Nkg2d ligands Ulbp1 and Ulbp2. Cancer Research. 2011;71(18):5998-6009. Epub 2011/07/19.
125. Yoon KW, Byun S, Kwon E, Hwang SY, Chu K, Hiraki M, Jo SH, Weins A, Hakroush S, Cebulla A, Sykes DB, Greka A, Mundel P, Fisher DE, Mandinova A, Lee SW. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 2015;349(6247):1261669. Epub 2015/08/01.
126. Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ. Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific Cd4(+) T cell responses. Immunity. 2014;40(5):681-91. Epub 2014/05/06.
127. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer. 2009;9(12):862-73. Epub 2009/11/26.
128. Vassilev LT. Mdm2 inhibitors for cancer therapy. Trends Molec Med. 2007;13(1):23-31. Epub 2006/11/28.